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The Relationship of Cyclic AMP Levels and Collagen Synthesis in Vascular Smooth 
Muscle Cells Following Estrogen or Beta-Adrenergic Treatment 
 
 
George John Dimopoulos, Ph.D. 
University of Connecticut, 2003 
 
The use of estrogens in postmenopausal women has become  
controversial. Estrogen replacement therapy has been used for many years to 
slow the progression of atherosclerosis. However, recent clinical studies have 
shown that menopausal women on hormone replacement therapy have higher 
incidences of myocardial infarctions and strokes than their counterparts without 
the therapy. Other studies have demonstrated that a decrease in collagen content 
in advanced atherosclerotic lesions may weaken the structural integrity of these 
lesions, resulting in rupture and clot formation. Within lesions, vascular smooth 
muscle cells (VSMCs) actively synthesize collagen and other types of extracellular 
matrix proteins during atherogenesis. Estrogen, through activation of the second 
messenger cAMP, may attenuate collagen synthesis in VSMCs and may promote 
reduction of collagen content in lesions. 
Incubation with Rp-cAMPs,  a PKA  inhibitor,  blocked  estrogen's  ability  to 
 
inhibit collagen synthesis in VSMCs. This suggests that estrogen, through 
stimulation of cAMP, may activate the cAMP-PKA pathway in VSMCs. Treatment 
of VSMCs with estrogen and phophodiesterase inhibitors, cilostamide or Ro-20-
1724, had an additive effect on increasing cAMP levels and on inhibiting collagen 
synthesis. VSMCs treated with estrogen and forskolin, an adenylyl cyclase 








and on attenuating collagen synthesis. When VSMCs were treated with both estrogen 
and a beta-adrenergic agonist, isoproterenol or terbutaline, there was an additive effect 
on cellular cAMP levels although the observed decrease in collagen synthetic rates 
were the same as observed in estrogen treated cells. VSMCs, which were treated with 
terbutaline, had a significantly higher amount of  cAMP located extracellularly 
compared to estrogen treated cells. The different distribution patterns of cAMP 
observed in terbutaline and estrogen treated cells may explain why beta agonists may 
not attenuate collagen synthesis in VSMCs. These results clearly demonstrate that not 
all agents, which elevate cAMP, may inhibit collagen synthesis in VSMCs. Our data 
also suggest that the combination of agents, which have an additive effect with 
estrogen, may have a negative effect on the stability of existing atherosclerotic lesions 
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Pathogenesis of Atherosclerosis 
 
Cardiovascular disease, accounting for approximately one million deaths 
annually, remains as the primary cause of death in the United States (National 
Institutes of health, 2002). Most cardiovascular deaths are attributed to myocardial 
and cerebral infarctions in blood vessels that exhibit atherosclerosis. 
Atherosclerosis is a disease primarily of the large to medium- sized arteries, which 
is characterized by raised focal plaques or lesions within the intima and media of 
the blood vessels. As plaques enlarge, they can impede blood flow to  tissue 
causing tissue necrosis and death. Atherosclerotic plaques can also serve as a 
focal point for the formation of blood clots, which if large enough can completely 
stop blood flow to tissues. (Parrish et al., 1967) The fatty streak is thought to be 
the earliest type of atherosclerotic lesion. It is a lipid-rich lesion, consisting of both 
lipid-laden macrophages and  vascular smooth muscle (VSMCs) (McGill et al., 
1968).  With increasing age, the fatty streak may progress and become an 
advanced, complicated plaque, composed of increased amounts of VSMCs, 
leukocytes, and intracellular and extracellular lipids (Ross et al., 1986).  This type 
of lesion is often surrounded by a dense fibrous cap of VSMCs and collagen (Fig. 
1) and is referred to as a fibrous plaque (Ross et al., 1986). 
The exact cause of atherosclerosis is unknown, however, factors, such as 
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infections are major risk factors for the development of atherosclerosis (Ross et 
al., 1976). Work by Ross and others suggest that these risk factors induce injury 
to the endothelial lining that initiates a variety of responses in the vascular wall,  


















Injury to Vascular Wall 
 




















Fig. 2 A schematic showing major risk factors causing injury to the arterial wall which results in 
the pathological manifestations of atherosclerosis. 
 
 
The Initiation of Atherosclerosis 
 
Both animal and human studies have suggested that atherosclerotic 
lesions are characterized by endothelial dysfunction, which is caused by injury 
to the endothelial lining of blood vessel (Petterson et al., 1993). In response to 
injury, endothelial cells begin to express adhesion molecules, selectins, 
intercellular adhesion  molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1]). These molecules are believed to aid in the recruitment 
of monocytes, T- lymphocytes, and other immune cells. (Cybulsky et al., 1991). 
Additionally, synthetic VSMCs stimulate monocyte and leukocyte recruitment 
during the early stages of atherogenesis by expressing VCAM-1 and ICAM-1
 
(Landry et al., 1997 and Poston et al., 1992). 
The expression of granulocyte-macrophage colony stimulating factor 
(GM-CSF), macrophage colony stimulating factor (M-CSF), and monocyte 
chemotactic protein 1 (MCP-1) by endothelial cells and activated macrophages 
have been reported to contribute to the early development of atherosclerotic 
lesions (Rajavashisth et al., 1990 and Boisvert et al., 1998). MCP-1 has been 
shown to promote chemotaxis and accumulation of additional monocytes to 
areas of lesion development (Boisvert et al., 1998). GM-CSF and M-CSF have 
been shown to stimulate differentiation, proliferation, and migration of 
macrophages and granulocytes, suggesting that these molecules may act as 
regulatory signals for modulating cell migration and proliferation during the early 
stages of atherogenesis. (Rajavashisth et al., 1990, Metcalf et al., 1989, 
Bussolino et al. 1989) . 
 
 
VSMC in Atherosclerosis 
 
Migration and proliferation of aortic vascular smooth muscle cells (VSMC) 
may play an important role in the formation of atherosclerotic lesions. Following 
injury to the endothelial lining VSMC become phenotypically altered and 
participate in the repair process of endothelial lining. Ross et al. (1993) have 
suggested that VSMC involvement during the repair process may become 





Phenotypic Regulation. VSMCs can present either a contractile or synthetic 
phenotype. In normal blood vessels, the majority of VSMCs are in a contractile 
phenotype and express a unique array of contractile proteins, receptors, ion 
channels, signaling molecules, and other proteins involved with cellular 
contraction (Owens et al., 1998). Contractile VSMCs proliferate and synthesize 
extracellular matrix proteins at extremely low rates, but once converted to a 
synthetic phenotype, as seen in vascular remodeling, these cellular processes 
are accelerated (Owens et al., 1995). The conversion of VSMCs to the synthetic 
phenotype is characterized by a reorganization of cytoplasmic microfilaments 
and organelles. Thyberg et al (1983) has shown that synthetic VSMCs have a 
reduced number of microfilaments and a larger number of organelles, such as 
rough and smooth endoplasmic reticulae, golgi, lysosomes, and mitochondria, 
which are responsible for the biosynthesis and secretion of macromolecules, 
such as collagen and glycosaminoglycans. 
Several studies have demonstrated that, during the atherogenic process, 
 
contractile VSMCs are transformed into synthetic VSMCs (Campbell et al 1981). 
The precise mechanism, by which VSMCs undergo a phenotypic transformation, 
remains elusive. Studies have shown that certain cytokines and prostaglandins 
promote the transition of VSMCs from a normal contractile phenotype to a 
synthetic one (Ross et al., 1981). MCP-1 and eicosanoids, such as, platelet 
derived 12-hydroxyeicosatetraenoic acid, neutrophil derived leukotriene B4, 




possible inducers of the secretory phenotype (Sjolund et al., 1984, Palmberg et al., 
1989 and Denger et al., 1999). 
In vitro studies have shown that culturing VSMC in fetal calf serum 
 
promotes conversion to the synthetic phenotype (Hedin et al., 1987). It is 
believed that growth factors in fetal calf serum induces phenotypic conversion, 
resulting in proliferation of cultured VSMCs (Hedin et al.,  1987). Other studies, 
examining VSMC growth on various types of matrix proteins, have reported that 
the extracellular milieu may play a role in phenotypic regulation of VSMCs. 
Contractile VSMCs cultured on type I collagen or fibronectin displayed 
conversion to the synthetic phenotype without the addition of exogenous 
mitogens (Thyberg et al., 1990). On the other hand, VSMCs grown on 
glycoprotein, laminin, or elastin, exhibited cell attachment, suppression of 
spreading, and retention of the contractile phenotype for several passages 
(Thyberg et al., 1990). Yamamoto et al. demonstrated that antibody blockage of 
the beta-1 integrin receptor in synthetic VSMCs prevented phenotype transition. 
These data suggest that VSMC integrin receptors are important for matrix-cell 
interactions, and the attachment to matrix proteins may promote VSMC 
phenotype modulation during atherogenesis (Yamamoto et al., 1993). 
Inducers of VSMC Proliferation and Migration During Atherogenesis. 
 
A host of diverse molecules, released from dysfunctional endothelial cells, 
platelets, synthetic VSMCs and/or various infiltrating immune cells, may alter the 
activity of synthetic VSMCs (Ross et al., 1976). MCP-1, basic fibroblast growth 
factor (bFGF), and platelet-derived growth factor B-chain (PDGF-BB) have been 
shown to stimulate proliferation of synthetic VSMCs (Viedt et al., 2002 and Linder 





Studies with adult rat synthetic VSMCs have shown that VSMCs are able to 
secrete a PDGF-like mitogen, which promotes cellular proliferation (Sjolund et 
al., 1988). 
Interleukin-1 and tumor necrosis-alpha (TNF-α), released by macrophages, also 
stimulate VSMC proliferation in addition to inducing VSMC expression of MCP-
1 (Cattaruzza et al., 2002). lnterleukin-3, which is secreted by activated T 
lymphocytes and is found in atherosclerotic lesions, may support atherogenesis 
by promoting proliferation and migration of VSMC within lesions (Brizzi et., 
2001). 
A variety of blood products can also stimulate VSMC migration and 
proliferation. At the site of blood vessel injury, platelets release heparinase and 
platelet factor 4, promoting the release of bFGF from the extracellular matrix of 
blood vessels. The release of bFGF has been shown to induce VSMC 
proliferation (Myler et al., 2002). Thrombin, a known mitogen of VSMCs, can also 
induce VSMC expression of the urokinase-type plasminogen activator. 
Urokinase-type plasminogen activator degrades fibrin through the conversion of 
plasminogen to plasmin, and. it is thought that this process promotes VSMC 
migration (Reuning et al., 1994). Other studies have shown that blood 
coagulation factors X, Xa, and protein S can also stimulate VSMC proliferation 
(Gasic et al., 1992). 
Other Possible Roles of Synthetic VSMCs. In addition to proliferative and 





ability to synthesize various types of macromolecules, which are involved in 
vascular remodeling in response to endothelial injury. (Ross et al., 1976). In 
response to PDGF treatment, cultured rat arterial VSMCs were shown to secrete 
MCP-1 (Poon et al., 1996). Poon et al. concluded that MCP-1 expression is a 
highly regulated process, which may be important in contributing to the 
inflammatory process during atherogenesis. In vitro studies have shown that 
MCP-1 induces interleukin-6 release from VSMCs (Viedt et al., 2002). 
lnterleukin-6 promotes differentiation of B lymphocytes into plasma cells that 
secrete antibody against various components of lesions. These 
immunomodulators may contribute to continuous inflammation within 
atherosclerotic lesions (Hansson et al., 1989 and Libby et al., 1995). GM-CSF, 
which is released from endothelial, can also be secreted by VSMCs, suggesting 
that both endothelial cells and VSMCs can stimulate proliferative activity in 
addition to inducing the migration of macrophages and granulocytes at the site 
of inflammation during the early stages of atherogenesis (Stanford et al., 2002). 
TNF-α, produced by both immune cells and endothelial cells and increases 
inflammatory and immune responses, is also released by VSMCs (Newman et 
al., 1998). The release of TNF-α by VSMCs may cause the infiltration of 
lymphocytes into lesions and may induce their activation (Newman et al., 1998). 
VSMC and Connective Tissue 
 
Synthetic VSMCs can synthesize enormous amounts of connective tissue 
proteins that promote vascular remodeling during atherogenesis (Burk et al., 
1979). Numerous types of connective tissue proteins (i.e., collagen, fibronectin, 




 the synthetic VSMC phenotype (Pietila et al., 1983). During atherogenesis, 
collagen production by VSMCs exceeds the synthesis of all other types of 
connective tissue proteins, and, thus, comprises the bulk of the lesion (Pietila et 
al., 1983). 
The Role of Collagen in Atherosclerotic Lesion Development 
 
It is well known that collagen molecules are structural macromolecules 
abundantly found in the extracellular matrix (ECM). Collagens are a family of 
complex proteins, which are comprised of 19 genetically distinct types (Wight et 
al., 1997). The general structure of collagen consists of a triple helix of 
polypeptide chains and globular domains. Collagen is unique in that it contains 
high amounts of the amino acid, hydroxyproline. Besides playing a structural role 
in vascular tissue, collagen has been shown to be involved with atherosclerotic 
lesion formation and lesion stability. High levels of collagen within lesions may 
lead to occlusions in blood vessels, while a deficit in collagen levels may make 
lesions more susceptible to rupture (Rekhter et al., 1998) 
Collagen comprises 60% of total protein within lesions (Smith et al., 1965). 
Collagen accumulation within lesions contributes to arterial lumen narrowing and 
may also further lesion development by serving as a depot for macromolecules, 




Taipale et al., 1997, and Vlassara et al., 1998). Studies have reported that 
collagens can interact with extracellular components in blood vessel walls, which 
may contribute in lesion development (Wright et al., 1989) Wight et al., (1989) 
observed that advanced atherosclerotic lesions that are abundant in type I 
collagen are also abundant in glycosaminoglycans (GAGs). In vitro studies have 
shown that GAGs can strongly link LDL to type 1 collagen, promoting retention 
of LDL in atherosclerotic plaques (Pentikainen et al., 1997). The mechanism by 
which GAGs link LDL to collagen is thought to involve both structural and 
electrostatic associations. The sulfated groups located on GAGs are highly 
negatively charged, and they can electrostatically bind to positively charged LDL 
and collagen (Danielson et al., 1997). A study by Hurt, involving isolation of 
chondroitin 6-sulfate rich proteoglycan from human aortas, demonstrated that 
GAGs bound to LDL via collagen molecules, caused a 2-4-fold increase in the 
uptake of cholesterol into human macrophages. Recent studies, employing 
electron microscopy and computer modeling, reported that the core protein of 
decorin, a predominant type of GAG macromolecule found in atherosclerotic 
plaques, has the shape of an arch which can insert itself in the triple helix of type 
I collagen (Scott et al., 1996 and Weber et al., 1996). 
In vivo studies, using a cholesterol fed rabbit model, demonstrated that 
hypercholesterolemia caused the formation of atherosclerotic lesions with a 
simultaneous increase in both LDL and GAG metabolism uptake and the 





al., 1975). Hoover et al., 1996 provided evidence that once LDL undergoes 
oxidative or metabolism, the resultant oxidized LDL binds to collagen. These data 
suggest that the internalization of oxidized LDL by macrophages may require the 
presence of both GAGs and collagen. Studies have also shown that oxidized- 
LDL may be a stimulant of collagen synthesis in aortic VSMCs. Jimi and 
colleagues (1995) found that oxidized-LDL increases collagen synthetic rates 
six- fold, while the native form of LDL had no effect in VSMCs. These studies 
suggest that oxidized LDL may help to initiate and sustain collagen synthesis in 
VSMCs (Jimi et al., 1995). 
The Role of Collagen in Lesion Stability 
 
Vulnerable atherosclerotic lesions can rupture and provide a site for the 
formation of a vessel-occluding blood clot, culminating in the clinical syndromes 
associated with many vascular diseases such as myocardial infarction or stroke. 
(Rabbani et al., 1999). The hallmarks of a vulnerable plaque include a large lipid 
pool, an abundance of inflammatory cells and mediators, a decreased smooth 
muscle cell population, reduction in collagen content, and a thin overlying fibrous 
cap (Rabbani et al., 1999). Rupture can commonly occur at the shoulder regions 
of lesions where the overlying fibrous cap is thin, necrotic and continuously 
infiltrated by macrophages (Constantinides et al., 1966). The shoulder regions of 
plaques are regions, which are exposed to the greatest hemodynamic forces 
(Cheng et al., 1993). The lipid core within lesions reduces the load-bearing 





promotes higher stress levels in the overlying fibrous cap, which may eventually 
rupture (Macisaac et al., 1993). 
Rises in blood pressure and coronary spasms can cause vulnerable 
lesions to rupture (Constantinides et al., 1990 and Nobuyoshi et al., 1991). 
Emotional stress and strenuous physical activity have been strongly associated 
with acute myocardial infarction (Totter et al., 1990). Both emotional stress and 
physical activity may cause myocardial infarct by elevating blood pressure and 
triggering coronary spasm. A study by Constantinides et al., 1966, demonstrated 
that in animal models, a sudden increase in arterial pressure can promote lesion 
rupture. After lesion disruption, the highly thrombogenic lipid components and 
the exposed collagen fragments may promote in the formation of an occlusive 
thrombus (Falk et al., 1995) 
Studies have shown that therapeutic strategies to lower lipid blood levels 
contributes to lesion stability (Rabbani et al., 1999). Elevated LDL levels have 
been intricately linked with endothelial dysfunction, and a reduction in LDL levels, 
using lipid-lowering drugs, has resulted in improved endothelial function 
(Anderson et al., 1995). Improving endothelial function by lowering LDL levels 
reduces the level of LDL infiltration within blood vessels, which reduces the 
amount of LDL that can collect within lesions (Anderson et al., 1995)). Decreased 
LDL pools within lesions resulted in a reduction of expressed matrix degrading 
enzymes and in an accumulation of interstitial collagen within the intima of 
atherosclerotic lesions of rabbits (Aikawa et al., 1998). Aikawa el al. suggested 





degradation of collagen. Additional studies have shown that increases in HDL, which 
is responsible for lipid removal from tissues, can increase the plaque's relative 
strength by stimulating collagen synthesis, thus favoring lesion stabilization 
(Blankenhorn et al., 1989). The conclusion of these findings emphasizes that 
circulating levels high LDL and low HDL may affect plaque stabilization by promoting 
a better balance between the amount of lipid in a lesion relative to the amount of 
collagen in the lesion (Rabbini et al., 1999). 
Factors Regulating Collagen Synthesis 
 
There are three primary factors, which may control collagen production 
within lesions. They are: 1) cell type, 2) cell activity, such as migration and 
proliferation, and 3) chemical and physical factors within atherosclerotic lesions 
(Rekhter et al., 1999). 
Cell Type 
 
Synthetic VSMCs, which migrate, proliferate, and produce increased 
amounts of collagen, are the most important contributors to the development of 
fibrous atherosclerotic plaques in blood vessels. Some studies have established that 
endothelial cells can also synthesize collagen during capillary vascularization in 
thicker plaques (Canfield et al., 1992). Cell types, such as stellate intimal cells and 
osteoblast-like cells, have also been shown to produce small amounts of type I 
collagen in human atherosclerotic lesions (Tintut et al., 1998  and Rekhter et al., 























Fig. 3. A schematic showing VSMCs and stellate smooth muscle-like cell within a lesion. 




Chemical and Physical Factors 
 
In adult rat and rabbit aortic VSMC cultures, there is a strong relationship 
between the conversion to the synthetic VSMC phenotype and collagen synthesis 
(Sjolund et al., 1986). Many studies have shown that upon phenotypic conversion to 
the synthetic from the contractile, VSMCs begin to synthesis and release collagen 
within the lesion (Thyberg et al., 1996). There are several local chemical factors 
which can alter collagen production in VSMCs. (Fig. 4). 
 
 
Fig. 4 A schematic showing a list of factors that may regulate collagen production in VSMCs. 








Studies of VSMC in culture have shown that PDGF induces synthesis of 
type I and Ill collagen. (Amento et al., 1991). The mechanism of PDGF 
stimulation of collagen synthesis in VSMCs is unknown. However, it is believed 
that PDFG is not a direct stimulator of collagen synthesis but rather a mitogen, 
which indirectly stimulates collagen synthesis through increase of cell 
proliferation (Rehkter et al., 1999). Interleukin-I, endothelin-I and angiotensin_ll 
have also been shown to stimulate collagen synthesis in SMC cultures (Rehkter 
et al., 1996). Angiotensin II stimulates collagen production in human arterial 
SMCs via the AT(1) receptor which results in an increases production of 
transforming growth factor beta {TGF-β) (Ford et al., 1996). 
TGF-β is a potent stimulator of collagen in VSMC cultures (Liau et al., 
1989). Nabel et al., has shown that in vivo transfer of the TGF-β gene into VSMCs 
of a porcine artery induced type I collagen production (Nabel  et al., 1993). 
Studies by Brenner et al. (1994), have shown that there is a TGF-β activation 
element in the promoter region of the alpha 1 (I) gene, which is responsible for 
activating transcription  of collagen. Connective tissue growth factor (CTGF), a 
protein, which is thought to be a downstream mediator for TGF- β signaling, has 
been shown to promote extracellular matrix formation by stimulating collagen 
synthesis in several cell types, including vascular endothelial cells, epithelial cells, 
neuronal cells, VSMCs, and fibroblasts. Additionally, CTGF has been shown to 
promote VSMC proliferation, migration, and adhesion. 
CTGF overproduction is proposed to play a major role in pathways that lead to 





(Moussad et al., 2000). CTGF, a 38-kDa cysteine-rich protein, is abundantly 
expressed in atherosclerotic lesions, but only marginally expressed in normal 
vascular tissues, suggesting that CTGF is one of the factors involved in the 
development of atherosclerotic lesions (Fan et al., 2002). Recent studies by 
(Duncan et al.,1999) demonstrated that elevation of intracellular levels of 
cAMP with either membrane-permeable 8-Br-cAMP or an adenylyl cyclase 
activator, cholera toxin, inhibited the ability of both TGF-β and CTGF to 
increase collagen synthetic rates in fibroblasts. Chen et al., 1999, investigated 
the ability of pentoxifylline to inhibit proliferation and collagen synthesis in rat 
VSMCs under both basal and PDGF or TGF-β stimulated conditions. 
Pentoxifylline is a phophodiesterase inhibitor that increases cellular levels of 
cAMP by preventing its metabolism. Chen and colleagues showed that 
pentoxifylline  inhibited both VSMC proliferation and collagen synthesis in a 
dose dependent manner. 
Cyclic AMP has been recognized as an inhibitor of collagen synthesis 
for many years. Studies by Baum et al. (1978) were the first to demonstrate in 
fibroblasts that elevation of cAMP levels reduced collagen production by as much 
as 40%. Increasing the levels of cAMP in cultured lung or skin fibroblasts by 
treatment with either prostaglandins, dibutyryl AMP, or the beta- adrenergic 
agonist, isoproterenol, resulted in decreased rates of collagen synthesis 
(Kollros et al., 1987) Clark et al., 1996 reported that PGE2 stimulated 
intracellular cAMP levels and decreased both lung fibroblast proliferation and 





investigated the mechanism by which the prostaglandin PGE 1 suppresses TGF- 
β- induced collagen synthesis in human corpus cavernosum smooth muscle cells. 
These studies demonstrated that PGE 1 inhibited TGF-β- induced collagen 
synthesis by invoking cAMP synthesis through the activation of adenylyl cyclase 
activity. 
Other studies using intestinal SMC reported that cholera toxin and isobutyl 
methylxanthine, agents which elevate cAMP levels, also significantly inhibited 
collagen synthesis. (Perr et al., 1989). The exact mechanism by which increased 
cAMP suppresses collagen synthesis is not known. However, because a variety of 
agents, which operate through different mechanisms, elevate cAMP  levels and 
suppress collagen production, it would suggest cAMP plays a central role. 
Estrogen and Atherosclerosis 
 
Post-menopausal women in their 50's and 60's experience an acceleration 
in coronary heart disease and usually match their male counterparts in the 
number of incidences of cardiovascular complications (Witteman et al., 1989). 
Estrogen replacement therapy has been used for many years to slow the 
progression of atherosclerosis. Recent epidemiological studies have strongly 
questioned this use of estrogen since it has shown that post-menopausal women 
on estrogen replacement therapy may experience an increased incidence of 
cardiovascular disease (Farquhar et al., 2002 and Lemaittre et al., 2002). Prior 
to these publications it was generally believed that the administration of estrogen 
to post-menopausal women decreased the risk of cardiovascular disease ( for 





mechanism of estrogen's perceived antiatherogenic effects has not been 
established. Studies suggested that estrogen had both lipid and non-lipid effects. 
The lipid effects include estrogen's ability to decrease both total cholesterol and 
LDL levels and to increase HDL levels (Bittner et al., 2000 and Lemay et al., 
2002). Some of the non-lipid mechanisms of estrogen action include decreasing 
insulin resistance, serum fibrinogen , factor VII, and plasminogen activator 
inhibitor-1 (Weidmann et al., 1985 and Kauser et al., 1994). Estrogens were also 
reported to maintain endothelial cell integrity, decrease expression of adhesion 
molecules, decrease platelet aggregation, inhibit VSMC proliferation, and exert 
antioxidant activity (for review, see Mendelsohn et al., 2002). Several studies 
have demonstrated that estrogen has a direct effect on inhibiting collagen 
synthesis in VSMC (Beldekas et al., 1981). During the early stages of 
atherosclerosis, the over production of collagen is an important component in the 
formation of complex fibrous atherosclerotic lesions (Okada et al., 1993). The 
natural presence or the administration of estrogens may aid in retarding the 
progression of plaques via inhibiting collagen synthetic rates in VSMCs. 
In vivo experiments, involving estrogen treatment of cholesterol-fed 
rabbits and estrogen treatment of renal hypertensive rats have shown that the 
administration of estrogen resulted in a reduction of aortic collagen synthesis in 
both the rat and the rabbit (Fischer et al., 1981). Ovariectomy of rabbits fed a 
high cholesterol diet resulted in an increased formation of atherosclerotic lesions 
(Fischer et al., 1981). Too, in cholesterol-fed rabbits an increase in the rate of 
aortic collagen synthesis was also evident (Fischer et al., 1981). Estrogen 





rabbits resulted in fewer atherosclerotic lesions with reduced levels of aortic collagen 
(Fischer et al., 1985). These studies suggested to Fischer et al. (1985) that 
estrogen's ability to inhibit atherosclerotic lesion formation was a result of estrogen's 
ability to reduce the rate of aortic collagen synthesis. These in-vivo observations 
were consistent with the initial observations of Beldekas  et  al., (1981) who found 
that treatment of VSMC in vitro resulted in a decreased production of collagen. The 
mechanism by which estrogen treatment reduces collagen synthesis is not 
completely understood but is probably related to estrogens ability to increase cell 
levels of cAMP. Studies by Dubey et al.,(2000) have shown that estrogen treatment 
of VSMCs results in a dose dependent increase in cellular levels of cAMP with 
corresponding decreases in collagen synthetic rates . Although the exact mechanism 
by which estrogen increases cAMP levels is unknown, studies have shown that 
stimulation of cAMP by estrogen in aortic VSMCs occurs via a calcium dependent 
process that does not involve nuclear transcription, suggesting that estrogen's 
effects on cAMP levels are mediated by direct interaction of the hormone with 
specific membrane binding sites (Farhat et al., 1996 and Dubey et al., 2000). 
Significance of Study 
 
The relationship of estrogen-induced changes in cAMP levels and 
collagen synthesis in the presence of other agents is not known. Tissue levels of 
cAMP are a product of its rate of synthesis minus its rate of metabolism. Cyclic 
AMP is synthesized from ATP by adenylyl cyclase and is regulated by many G- 




combination of hydrolysis, which is catalyzed by cyclic nucleotide 
phosphodiesterases, and efflux by several plasma membrane transport proteins. In 
most instances cAMP produces its effects by activating cAMP- dependent protein 
kinases, which in turn phosphorylate a variety of molecules, such as metabolic 
enzymes, transport proteins, and numerous  regulatory proteins (Chin et al., 2002) 
There are several clinically used agents, which have the potential to significantly 
alter cell cAMP levels by either altering its rate of synthesis or elimination. Since 
changes in cAMP levels could have a significant effect on collagen synthesis in 
VSMC, it is important that the relationship of estrogen, cAMP and collagen synthesis 
should be investigated. The hypothesis, which was investigated in this study, is that 
agents which elevate cAMP, when used in combination with estrogen, will have an 












Male Sprague -Dawley rats (Charles River Laboratories),  weighing between 
190-220 grams, were used for the purpose of isolating vascular smooth muscle cells 
(VSMC). Rats were housed three per cage at 27 °C with a 12-hour light and dark 
cycle. Commercial Purina Rat chow and water were provided ad 
libitum. All rats were fasted overnight prior to VSMC isolation.  All procedures 
were approved by the University of Connecticut Animal Care Committee. 
Drugs, Cell Culture Reagents, Isotopes, and other Chemicals 
 
1713 Estradiol, isoproterenol, propranolol, terbutaline, forskolin, 
pentobarbital, elastase, collagenase, and trichloroacetic acid were purchased 
from Sigma Chemical (St. Louis, MO). Cilostamide and Ro-24-1720 were 
purchased from Calbiochem-Novabiochem (San Diego, CA). Hanks Balanced 
Salt Solution, Medium 199, fetal bovine serum, penicillin-streptomycin, 
kanamycin, and 
amphotercin B were purchased from BRL Gibco Life Technologies (Rockville, MD). 
[14C] L-proline was purchased from Amersham Pharmacia Biotech (Piscatawey, 
NJ). Optiflour scintillation fluid  was purchased  from Perkin Elmer Life Sciences 
(Beltsville, MD). 
Isolation of Cells 
 
Rats were killed with a lethal injection of pentobarbital at dose of  120  mg/kg 
and the thoracic cavity was opened immediately. The  aorta, from the aortic arch to 
the femoral bifurcation, was quickly removed  and cleaned under cold running tap 




isolated aorta was removed by blunt dissection and the remaining aorta was placed 
in sterile Hanks Balanced Salt Solution (HBSS) pH 7.5. HBSS contained 2.7uM 
amphotercin B, 250units/ml penicillin-streptomycin and 170uM kanamycin. The 
intima from each aorta was removed by scraping with a rubber  policeman, and the 
remaining medias were minced into  small  cuboidal  pieces in HBSS. The minced 
medias were digested in plain sterile Medium-199, pH 7.5, 
containing  2mg/ml collagenase  and 0.4 mg/ml elastase  for 3 hours  at 37 °c in a 
shaking water bath. After digestion, cells were initially plated in 25 cm flasks and 
were left in the flask for eight days. Studies have reported that all freshly isolated 
VSMCs should be in the synthetic phenotype by the eighth day in culture (Thyberg 
et al., 1983). Following the eighth day, VSMCs were divided and replated into two 
separate flasks, and the cells were allowed to grow to confluency. This step was 
repeated eight times to propagate adequate numbers of cells for experiments. 
Characterization of VSMCs 
 
Two methods were used to characterize VSMCs following isolation from 
aorta. The first method consisted of immunohistochemistry of a specific isoform 
of the alpha-actin cytoskeletal protein exclusively found in VSMCs. The second 
method included morphological studies of VSMCs in confluent cultures. 
Confluent VSMCs have a characteristic "hill and valley" pattern that can be 









To assess the identity of VSMCs after isolation, detection of VSMC actin 
levels was conducted with the Ultra Streptavidin Detection System (Signet 
Laboratories, Dedham, MA). The primary antibody used in this study is specific 
for the actin that is only found in VSMCs (Owens et al., 1986). Isolated cells were 
grown on cover slips for 24 hours and then were fixed with 100% acetone for 
four minutes. Samples were rinsed with phosphate buffered saline (PBS) for 
three minutes and then were treated for five minutes with normal serum to block 
nonspecific binding. Primary antibody, specific for VSMC actin, was incubated 
with samples overnight at 4°C. Primary antibody serial dilutions of 1:40, 1:30, 
and 1:20 were used on test samples to ascertain correct dilution for adequate 
staining of VSMCs. This step demonstrated that 1:30 dilution was optimal for 
staining VSMCs. After the primary antibody wash step, cytology samples were 
incubated with biotinylated anti-immunoglobulin serum linking reagent 
(secondary antibody) for 20 minutes at room temperature, and the peroxidase 
labeled ultra-streptavidin was incubated with samples for an additional 20 
minutes at room temperature. The first 20-minute incubation allowed the binding 
of secondary antibody to the primary antibody, while the second 20-minute 
incubation allowed the peroxidase to bind the secondary antibody. Lastly, the 
substrate chromogen, 3-amino-9-ethylcarbazole (AEC), was incubated with 
samples for five minutes at room temperature to allow the chromogen to react 








. Each experiment consisted of incubating VSMCs with various 
experimental agents for one hour. VSMCs were plated with M-199 medium and 
15% bovine serum in six well plates with a diameter of 35mm, and these cells 
were then grown to 70-80% confluency. Before experimentation, each well was 
washed twice with plain M-199 medium, and the appropriate agent(s) was/were 
prepared in M-199 medium and dispensed in duplicate or triplicate into 
designated wells. Separate studies were conducted for ascertaining cAMP levels 
and protein synthetic rates. To reduce variability, the values obtained from two-
three separate wells were averaged and were reported as a single experimental 
value (N=1) for all studies. 
 
 
Determination of Protein Synthetic Rates 
[14C]-L-Proline Incorporation [14C]-L-proline incorporation was utilized to  assess the 
rate of collagen, and non-collagen,  protein synthesis in VSMCs. Treated cells 
were incubated with isotope for one hour at 37°C. Preliminary studies were 
conducted to determine the proper conditions for  incorporation  of  14 C-proline. The 
results of these studies suggested that a 1-hour incorporation would allow for 
accurate determination of either inhibition or stimulation of protein synthetic rates. In 
all experiments VSMCs were incubated with experimental agents and isotope for 1 
hour. Upon completion of the 1- hour  incubation  period, controls and treated 
samples were placed on ice. Cell medium  was  aspirated  from each  well and placed 







each well were loosened by scrapping and were then suspended in 100mM EDTA. 
VSMCs were then  sonicated 3 times for 30 seconds, and 100ul of the resulting 
homogenate was set aside for assessing the total protein concentration for 
normalizing the collagen and non-collagen synthetic rates (e.g., cpms/mg/ml 
protein). The remaining protein in the cell homogenate was precipitated in 5% TCA 
by adding  an appropriate  volume  of 10% trichloroacetic acid (TCA) to each sample. 
Both cell medium and homogenates  were then combined  and centrifuged  at low 
speeds (800xg) for 5 minutes. 
Supernatant, containing unincorporated [14 C]-L-proline, was discarded, 
and the pellets were resuspended with 4ml of 5% TCA and centrifuged at 800xg 
for five minutes. This wash step was repeated 6 times to ensure that all 
unincorporated [14 C]-L-proline is removed. 
 
 
Trichloroacetic Acid Extraction Assay 
 
The hot TCA extraction procedure was utilized to separate collagen from 
other cell proteins. The amount of collagen in tissues can be estimated by 
measuring tissue levels of hydroxyproline, an amino acid which is primarily found 
only in collagen. Hydroxyproline in collagen is formed by the post-translational 
hydroxylation of one of the prolines in the repeating amino sequence of G-P-P, 
which is common to collagen. Studies have reported that treatment of collagen 
with TCA at 90°C solubilizes collagen by hydrolysis of the peptide bond between 
proline and hydroxyproline (Last et al., 1975). In our studies, after samples were 




collagen synthesis, and the remaining pellet was used to determine non-collagen 
protein synthesis. 
Homogenate samples were hydrolyzed in 5% TCA by incubating the 
samples in a 90 °c water bath for 60 minutes. The hydrolyzed samples were then 
centrifuged at 800xg for 10 minutes. Supernatant samples, containing collagen, 
were collected in separate tubes and the pellets, consisting of non-collagen protein, 
were resuspended with 0.5N NaOH. A 0.5 ml aliquot of each sample (collagen and 
non-collagen) was placed in 5ml of scintillation cocktail, and the radioactivity of 
incorporated [14C] L -proline was determined by liquid scintillation counting. The 
average of two 10-minute counts were used in all experiments to obtain a statistically 
significant number of counts. All data were expressed as counts per minute (CPMs). 
Cyclic AMP Levels 
 
Cyclic AMP levels were assessed by either the [3H] cAMP detection 
system (Amersham Pharmacia Biotech, Piscatataway, NJ) or the cAMP enzyme 
immunoassay system (EIA) (Amersham Pharmacia Biotech, Piscataway, NJ). 
The preparation steps for both cAMP detection systems were identical. After 
experimentation, VSMCs were immediately placed on ice. The incubation 
medium from VSMCs was removed and placed into separate tubes. VSMCs 
were then resuspended in 100mM EDTA and were then sonicated twice for 30 
seconds. A 100 µl aliquot from each sample was placed into separate tubes for 
determining total protein concentrations. Total protein concentrations were used 







each sample were combined and boiled for seven minutes to coagulate protein. 
Samples were then centrifuged at 800xg for 10  minutes, and the resulting 
supernatant was assayed for cAMP content. 
Principles and Protocols of cAMP Assays 
 
The [ 3H] cAMP detection system is based on competition between unlabeled 
cAMP (sample) and a fixed quantity of tritium labelled  cAMP  for binding to a protein 
which has a high affinity for cAMP (Gilman et al., 1970). The amount of labelled 
cAMP -protein complex formed is inversely related to the amount of unlabeled cyclic 
AMP present in the assay. The  concentration  of cAMP in the unknown is assessed 
by comparison with a standard curve. (2pmol- 32pmol). 
100ul of sample or standard were added to 1.5ml microcentrifuge tubes. 
A 50ul aliquot of labeled cAMP was added to each of the samples, which was 
followed by the addition of 100ul of binding protein. After a 2-hour incubation 
period at 4°C, separation of the protein bound cAMP from the unbound cAMP 
(labeled/unlabeled) was accomplished by adsorption of free cAMP on charcoal, 
followed by microcentrifugation (800xg) (Brown et al., 1971). A 200ul aliquot of 
the supernatant was removed for liquid scintillation counting as described above. 
The cAMP enzyme immunoassay system (EIA) is based on competition 
between unlabeled cAMP (sample) and a fixed quantity of peroxidase-labelled 
cAMP, for a limited number of binding sites on a cAMP specific antibody. The 
peroxidase-labeled cAMP conjugate is immobilized onto pre-coated microtiter 





the unknown sample is inversely related to the amount of peroxidase-labelled cAMP, 
which is bound to the cAMP specific antibody. The amount of unknown cAMP in 
each sample was determined by comparison with a linear standard curve which was 
determined for each experiment using a 3200 fmol/ml cAMP standard stock solution. 
Beginning with the standards and ending with the unknowns, a volume of 
100µl of each sample was added to the specified well plate. Next, a volume of 100µl 
of cAMP antibody was added to the sample wells, and these samples were 
incubated for two hours at 4°C. Immediately following the 2-hour incubation, 50µl of 
cAMP-peroxidase conjugate was added into the wells, and the samples were 
incubated for 1 hour at room temperature. Following a wash step to remove excess 
antibody, samples were treated with 150µl of tetramethylbenzidine (TMB), which 
reacts with the bound cAMP-peroxidase conjugate, for one hour at room 
temperature. Upon completion of the enzyme substrate incubation, 100µl of 1.0M 
sulfuric acid was added into the well to stop the reaction, and each well was read by 
a fluorimeter (Dynex Corporation) at an optical density of 450nm within 30 minutes. 
Blank and nonspecific binding wells were included along with the sample wells. 
Protein Assays 
 
The Bicinchoninic Acid Protein Assay Kit (BSA) (Pierce, Rockville, IL) or 
the Coomassie Plus Protein Assay Kit (Pierce, Rockford, IL) was used to 
determine the protein concentrations of each sample. Total protein 






collagen, and total protein synthetic rates. A Linear standard curve 25-240 g/ml 




The statistical significance of the data from each study was analyzed by use of a 
one-way ANOVA to test for the overall treatment effect. If a significant difference 
was indicated, the data was further analyzed using Tukey's procedure.  Data which 







Immunochemical and histological procedures were used to characterize  
isolated vascular smooth muscle cells (VSMC). lmmunohistochemistry was 
utilized to identify a specific isoform of the α-actin cytoskeletal protein, which is 
unique to SMCs. As shown in Fig. 5A, the reddish- brownish staining of α-actin 
cytoskeletal filaments, suggests that the isolated cells were VSMCs. 
Histologically, the distinct spindle-shape morphology and the hill-valley pattern 
of these cells in culture is also a recognized a unique characteristic of VSMCs. 
To ensure that the isolated cells were not fibroblasts, mouse fibroblasts were 
immunochemically stained for α-actin. As seen in Fig. 5D, the mouse fibroblasts 
exhibited an absence of staining for α-actin, which was expected since fibroblasts 
lack α- actin. 
The ability of estrogen to stimulate the production of cAMP in VSMCs is 
shown in Fig. 6 . VSMCs, incubated  with increasing concentrations (10-6    104 
M) of  estradiol  for 1 hour, resulted in a  corresponding  increase in cAMP from 
control levels of approximately 10 pmoles/mg protein to 40 pmoles/mg protein. 
The effect of increasing concentrations of estradiol on collagen and non-collagen 
protein synthesis is shown in Fig. 7. When cells were incubated for 1 hour with 
concentrations of estradiol ranging from 10-6 to 104 M there was a corresponding 
decrease in the rate of collagen and non-collagen protein  synthesis  in VSMCs. 
The potential correlation between increasing amounts of cAMP and decreasing 




and is shown in Fig. 8. In Fig 4, the percent increase in cell cAMP levels, invoked by 
increasing concentrations of estradiol, was plotted against the percent inhibition of 
collagen synthesis. Analysis of the data showed a correlation coefficient of 0.88, 
which was statistically significant at P <0.1. 
The purpose of this study was to examine the relationship of cAMP-protein 
kinase and estrogen's ability to inhibit collagen synthesis. Several studies have 
shown that cAMP activates the cAMP-protein kinase A pathway to elicit various 
cellular processes (Chin et al., 2002). As shown in Fig. 9, treatment of VSMCs 
with the protein kinase inhibitor, Rp-cAMP (10-5 M) for 1 hour completely 
inhibited  estradiol’s (10-5 M)  inhibition of collagen synthesis in VSMCs. 
The ability of inhibitors of cAMP metabolism to alter cAMP levels and 
collagen synthesis, when used alone or in combination with estradiol, was 
investigated with phosphodiesterase inhibitors. Treatment of VSMCs with Ro-20-
1724 (10-6 M), an inhibitor of phosphodiesterase type 4, resulted in a significant 
increase in cAMP levels. Cyclic AMP levels were approximately 5- fold greater 
than the amounts observed with just estradiol alone. When estradiol and Ro-20-
1724 were combined there was a significant increase in cAMP levels compared 
to just estradiol treated cells (Fig 10). Treatment of VSMCs with either estradiol  
(1. 0 5M) or Ro-20-1724  (10-6  M)  resulted  in  a  50%  inhibition of both collagen 
and total protein synthesis (Fig 11). The combination of estradiol and Ro-20-






which was significantly greater than the reduction observed when either agent  
used alone (Fig 11). Treatment of VSMCs with cilostamide (10-6 M), an inhibitor 
of phosphodiesterase type 3, also resulted in a significant increase in cAMP 
levels (Fig. 12). Cyclic AMP levels were the same as observed with just estradiol 
alone. Co-treatment of estradiol and cilostamide resulted in cAMP levels that 
were significantly greater than those observed in VSMCs treated with estrogen 
alone (Fig 12). Treatment of VSMCs with either estradiol (10-5M) or cilostamide 
(10-6 M) resulted in an 50% inhibition of both collagen and total protein synthesis 
(Fig 13). The combination of estradiol and cilostamide reduced both collagen and 
total protein synthesis, which was significantly greater than the reduction 
observed when either agent was used alone (Fig 13) but was similar to the effects 
observed when cells were treated with Ro-20-1724 (Fig. 11). 
Levels of cAMP and protein synthesis were estimated in VSMCs following 
forskolin  (10-6M ) induction of adenyl cyclase. Treatment of VSMCs for 1 hour with 
forskolin resulted in a significant  increase in cAMP levels when compared to either 
control or estradiol treated  cells  (Fig. 14). The combination  of VSMCs with estradiol  
and forskolin appeared resulted in an increase in cAMP levels (Fig 15).  Although 
treatment  of cells with forskolin resulted in  a reduction in collagen and total protein 
synthesis, this reduction was similar to the inhibitory effect seen with estradiol 
treatment even though forskolin treatment resulted in a much greater increase in 




by estradiol. The combination of estradiol with forskolin resulted in a further 
reduction in collagen and total protein synthesis (Fig. 15). 
Changes in levels of cAMP and collagen and total protein synthesis were 
investigated in VSMCs following stimulation or inhibition of autonomic beta-
adrenergic receptors. Treatment of VSMCs with isoproterenol, a beta agonist, 
for 1 hour significantly increased cAMP levels compared to control or estradiol 
treated cells (Fig. 16). The combination of estradiol plus isoproterenol resulted in 
an additional increase in cAMP levels compared to  treatment of VSMCS with  
isoproterenol alone. Treatment of cells with propranolol, a beta antagonist, for 1 
hour resulted in no significant changes in cAMP levels. The combined treatment 
of cells with propranolol plus isoproterenol significantly reduced cAMP levels 
compared to cells treated with just isoproterenol. The administration of 
propranolol to estrogen treated cells had no significant effect on cAMP levels. 
Treatment of VSMCs with isoproterenol, for 1 hour had no significant 
effect on collagen or total protein synthesis (Figs 17, 18). This was true whether 
the cells were incubated with isoproterenol for 1 hour (Figs.17, 18) or 6 hours 
(Fig. 19). Treatment of cells with propranolol had no effect on collagen or total 
protein synthesis. The combination of either isoproterenol or propranolol with 
estradiol resulted in a decrease in collagen and total protein synthesis, which was 
similar to treatment with only estradiol (Fig. 17, 18). 
To further evaluate the effects of beta stimulation on VSMC cAMP levels and 
collagen and total protein synthesis, cells were treated with terbutaline (10-6 M), a 




hour resulted in a significant increase in cAMP levels, which was similar to levels 
observed in VSMCS with just estradiol alone.  When  cells were treated  with 
estradiol plus terbutaline, cAMP levels were significantly greater than  the levels 
seen in cells treated with  just  estradiol  (Fig. 20).  Incubation  of VSMCs with 
terbutaline had no effect on collagen or total protein synthesis  (Fig.  21). When 
terbutaline was co-administered with estradiol, the rate of collagen and  total protein 
synthesis was the same as observed when cells were treated with  estradiol alone 
(Fig. 21). The ratio of cellular to extracellular location of cAMP following either 
estradiol or terbutaline are shown in Fig 22. Following  treatment with estradiol 
approximately, 40% of cAMP was located intracellularly, while  60% was located 
extracellularly. This distribution of cAMP was also observed  in  non-estradiol treated 
control VSMCs.  In VSMCs treated with terbutaline, only 10% of cAMP was located 
intracellularly and 90% was located  extracellularly.  This  relative  distribution  of  
cAMP  was  significantly  different  from  the  distribution of cAMP seen in control or 












Fig. 5 lmmunohistochemical identification of alpha-actin in isolated cells. (SA) 
isolated cells without alpha-actin antibody. (5B) Isolated eels with alpha-actin staining.; 
note the reddish-brownish staining of cells, confirming the presence of alpha-actin. (SC 
& D) shows alpha-actin antibody staining of fibroblasts. (SC) fibroblasts, without alpha- 
actin antibody. (5D) Fibroblasts with alpha-actin staining. Note no staining in both the 












































Fig. 6. The effect of varying concentrations of estrogen on cAMP levels in VSMCs. 
VSMCs were treated with estradiol for one hour and were then assayed for cAMP as 
described in methods. In this figure a dose response relationship demonstrates that 
increasing estradiol concentrations (10-6 M - 104 M) results in increasing cAMP levels 
(pmoles/mg protein) in VSMCs. Each point represents the mean of three observations 
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Fig. 7. The effect of varying concentration of estradiol  on  collagen  and noncollagen 
synthetic rates in VSMCs. VSMCs were treated with estradiol and 14C-L- proline for one 
hour, and were assayed for collagen and noncollagen synthesis as described in methods. 
In this figure a dose response relationship demonstrates that increasing estradiol 
concentrations (10-6 M - 104 M) can result in decreasing levels of collagen and non-collagen 
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Fig. 8. The relationship of estradiol induced  changes  in cellular  levels  of cAMP and 
collagen synthesis  in VSMCs.  A regression  analysis  of the data in Figures 2 and 3 was 
conducted to determine the relationship between changes in VSMC cAMP levels and rates 

















































Fig. 9. The effects of Rp-cAMPs  on estradiol's inhibition of protein synthesis in 
VSMCs. VSMCs were incubated with agents and 14C-L-proline for one hour and were 
assayed for protein synthetic levels as described in methods. Estradiol 10·5 M reduced 
collagen synthesis. Rp-cAMPs 1o.s M had no effect  on collagen  synthesis.  Estradiol 
1o.s M + Rp-cAMPs  10·5 M   treatment  had no effect on collagen  synthesis.   Each value 


































Fig. 10. The effects of estradiol and Ro-20-1724  on  cAMP  levels  in  VSMCs. VSMCs 
were incubated with agents for one hour and were assayed for cAMP as described in 
methods. Estradiol 10 -5 M significantly elevated cAMP two fold, while Ro- 20-1724 10-6M 
elevated cAMP approximately 10 fold. Treatment of VSMC with estradiol 10-5 M + Ro-20-
1724 10-6M had an additive effect on cAMP levels.  Each  value represents the mean± SE 











































































Fig. 11. The effects of estradiol and Ro-20-1724 on collagen and total protein 
synthetic rates in VSMCs. .  VSMCs were incubated with agents and 14C-L-proline for 
one hour and were assayed for collagen and total protein synthetic rates as described 
in methods. Estradiol 10-S M and Ro-20-1724 (Ro) 10-6 M reduced both collagen and 
total protein synthesis by 50%. Treatment of VSMCs with estradiol 10-5 M 
+ Ro-20-1724 10-6 M significantly reduced collagen and total protein synthesis when 
compared to treatment of cells with estrogen or Ro-20-1724 alone.  Each  value represents 
the mean ±_SE of six observations. *  p< 0.05 compared  to control  cells.  ** p< 0.05 



































Fig. 12. The effects of estradiol and cilostamide on cAMP levels in VSMCs VSMCs 
were incubated with agents for one hour and were assayed for cAMP as described in 
methods. Estradiol (Estra) 10-SM and cilostamide (Cilo) 10 M significantly increased 
cAMP  levels  in  VSMCs.      The  combination  of  estradiol  1o-5 M  +  cilostamide  10 M 
resulted in a significantly increase in cAMP levels when compared to estrogen treated cells. 
Each value represents the mean .:!: SE of seven to ten observations. * p< 0.05 compared 
to control cells ** p< 0.05 compared to estradiol treated cells 
 
































































Fig. 13. The effects of estradiol and cilostamide on collagen and total synthetic 
rates in VSMCs.  VSMCs were incubated with agents and 50µCi 14C-L-proline for one 
hour and were assa1,ed for collagen synthetic levels. Treatment of VSMCs with either 
Estradiol  (Estra)  10  M  or  Cilostamide  (Cilo)  1-0   5M  significantly  reduced  collagen  and 
total protein synthetic rates.  Treatment of cells with estradiol 1o-5 M + cilostamide  10-6M 
had additive effect on both collagen and total protein synthetic rates. Each value represents 
the mean .:!:. SE of five to ten observations. * p< 0.05 compared  to control  cells. ** p< 0.05 
































Fig. 14. The effects of estradiol and forskolin on cAMP levels in VSMCs. VSMCs  were 
incubated with for one hour and were assayed for cAMP as described in methods. Estradiol 
(Estra) 10-SM significantly increased cAMP levels. Forskolin (Fors) 10-sM significantly 
increased  cAMP levels  compared  to estrogen  treated cells. Estradiol 10-SM 
+ forskolin 10-sM appeared to have an additive effect on cAMP levels compared to the cells   
treated  with  just  forskolin.     Each  value  represents   the  mean  ±.  SE  of three 


































































Fig. 15. The effects of estradiol and forskolin on collagen and  total  protein synthetic 
rates in VSMCs. VSMCs were incubated with agents  and  2.5µCi  14C-L- proline for one 
hour and were assayed for collagen and total protein synthetic levels. Estradiol (Estra) 10·5M 
and forskolin (Fors) 10-6  M both  significantly  reduced  collagen and total protein synthesis. 
Treatment of VSMCs with estradiol 10·5M+forskolin 10 M 
significantly reduced collagen and total protein synthesis compared to estradiol treated 
cells Each value represents the mean ±. SE of six observations. * p< 0.05 compared to 














































Fig. 16. The effect of estradiol and isoproterenol on  cAMP  levels  in  VSMCs. VSMCs 
were incubated with agents for one hour and assayed for cAMP. Estradiol (Estra)10-5M, 
significantly increased cAMP levels 2 fold, while isoproterenol (lso) 10-e M significantly 
increased cAMP levels 5 fold .,The combination of isoproterenol + estrogen appeared to 
have an additive effect on cAMP levels. Propranolol  (Pro) 10-eM alone had no effect on 
cAMP levels, but significantly decreased isoproterenol 's stimulation of cAMP levels 
Propranolol had no effect on estrogens ability  to increase  cAMP  levels.  Each value 
represents the mean .! SE. of at least four observations. * p<0.05 compared to control cells. 
 














































Fig. 17. The effect  of estradiol  and isoproterenol  on collagen synthetic rates in 
VSMCs. . VSMCs were incubated with agents and 14C-L-proline for one hour, and were 
assayed  for collagen synthetic activity as described in methods.   Estradiol  (Estra) 1o-s M 
significantly reduced collagen synthesis by 50%, while isoproterenol (lso) and 
propranolol (Pro) had no effect on collagen synthetic activity. .The combination of either 
isoproterenol or propranolol with estrogen had no effect on estrogen's ability to inhibit 
collagen synthesis. Each value represents the mean ±. SE of five observations. * p< 


















































Fig. 18. The effect of estradiol and isoproterenol on total protein synthetic rates in 
VSMCs. VSMCs were incubated with agents and 14 C-L-proline for one hour, and were 
assayed for total protein synthetic activity as described in methods.  Estradiol (Estra) 10-5 
M significantly reduced total protein synthesis by 50%, while isoproterenol (lso) and 
propranolol (Pro) had no effect on total protein synthetic activity. The combination  of either 
isoproterenol or propranolol with estrogen had no effect on estrogen's ability to inhibit total 
protein synthesis. Each value represents the mean + SE of five observations.  * p< 0.05 
compared to control cells. 





































Fig. 19. The effect of a prolonged incubation with isoproterenol on collagen, non- 
collagen, and total protein synthetic rates in VSMCs VSMCs were incubated with 
agent and 14C-L-prolinefor six hours and were assayed for collagen, noncollagen, and 
total protein synthetic levels as described in methods. isoproterenol 10-6 M had no effect 
on collagen, non-collagen, or total protein synthetic rates. Each value represents the 
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Fig. 20. The effect of estradiol and terbutaline on cAMP levels in VSMCs. VSMCs were 
incubated with agents for one hour and were assayed as described in methods. Estradiol 
(Estra) 10-5 Mand terbutaline (Terb)10-6 M significantly  increased  cAMP levels 2 -fold. 
Treatment of VSMCs with estradiol 10·5 M + terbutaline 10-6 M had an additive, elevating 
cAMP levels three fold. Each value represents the mean.:!: SE of four to five observations. 

















































Fig. 21. The effect of estradiol and terbutaline on collagen and total synthetic 
rates in VSMCs. VSMCs were incubated with agents and 2.5µCi of 14C-L-proline for 
one hour and were assayed for collagen and total synthetic levels as described in 
methods. Estradiol (Estra) 10-5 M significantly reduced collagen and total synthesis. 
Treatment of VSMCs with estradiol 10-SM + terbutaline 1o-oM also significantly reduced 
both collagen and total protein synthesis. Terbutaline 10-0 Malone had no effect on 
collagen or total protein synthesis. Each value represents the mean ± SE of three 
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Fig. 22. The effects of estradiol and terbutaline on intracellular and extracellular cAMP 
levels in VSMCs. VSMCs were incubated with agents for one hour, and the medium   and   
cellular   extracts   were   assayed   for  cAMP   as   described   in methods. 
Treatment of VSMCs with Terbutaline (Terb) 10  M resulted in 90% of total cAMP in the 
extracellular environment. Control and estradiol (Estra) 10.sM treated cells had significantly 
less  cAMP  in  the  extracellular  milieu  and  significantly  more  cAMP intracellularly 
compared  to the terbutaline treated  cells.   Each value represents  the mean. 











The use of estrogens in postmenopausal women has recently become 
controversial. Estrogen replacement therapy has been used for many years to 
slow the progression of atherosclerosis. Recent studies have suggested that 
estrogen replacement therapy may inflict harmful effects, such as myocardial 
infarcts and strokes than beneficial effects. Estrogens have been shown to   
inhibit collagen synthesis (Dubey et al. 1998). Collagen is known to have an 
important role in atherosclerotic lesions, and its accumulation within 
atherosclerotic lesions is known to promote narrowing of the arterial lumen and 
may serve as a depot for macromolecules (i.e., lipoproteins and growth factors). 
Other studies have suggested that collagen may add to lesion stability (Rekhter 
et al., 1999) and that a decrease in collagen can make atherosclerotic lesions 
vulnerable to rupture, which may promote the formation of vessel-occluding 
blood clots. These data suggest that either too much or too little collagen within 
atherosclerotic lesions could have a negative effect on blood flow in diseased 
blood vessels. The mechanism by which estrogen treatment reduces collagen 
synthesis is not completely understood but is probably related to estrogens ability 
to increase cell levels of cAMP. The hypothesis, which was investigated in this 
study, was the following: agents, which elevate cAMP in VSMC, when used in 
combination with estrogen, will have an additive effect in inhibiting collagen 





There are many studies that show estrogen eliciting a fast-acting 
biological response through nongenomic processes in a variety of cell types 
(Dos Santos et al., 2002, Cambiasso et al., 2001, and Farhat et al., 1996). Our 
results demonstrate that increasing concentrations of estrogen (10-6M, 10-5M, 10- 
4M) resulted in elevated levels of cAMP in VSMCs and that estrogen at a dose of 
10-5M can increase cAMP levels 2-fold within 1 hour.(Fig. 6). These results agree 
with recent study data by Farhat et al., (1996) and Dubey et al., (2000), which 
demonstrated that estrogen may induce cAMP within 5-30 minutes in VSMCs. 
Farhat et al. further demonstrated that estrogen increases cAMP levels by 
stimulating adenylate cyclase activity through a calcium-dependent process. 
Estrogen is an inhibitor of collagen synthesis in VSMCs; however, the exact 
mechanism is not known. One of the first studies investigating estrogen effects 
on collagen synthesis showed that estrogen inhibited total collagen production 
and reduced procollagen type 1 and type 2 fractions in bovine aortic smooth 
muscle cells (Beldekas et al., 1981 and Dubey et al.2000), demonstrated that 
estrogen, increased cAMP levels, which resulted in inhibition of both, total 
protein and collagen synthesis. The results from our studies agree with the 
findings of Dubey et al., In our study, VSMCs treated with increasing 
concentrations of estrogen displayed decreasing rates in both collagen and 
noncollagen protein synthesis in addition to increasing levels of cAMP, 
suggesting a dose response relationship (Fig.7). When collagen synthetic rates 
in VSMCs were compared to cellular levels of cAMP, there was an apparent 





a related reduction in collagen synthesis followed. (Fig. 8). The mechanism by 
which increased cAMP levels reduces rates of collagen synthesis is unknown. 
Dubey and colleagues suggested that estrogen inhibits protein synthesis in 
VSMCs by activating a cAMP-adenosine pathway (Dubey et al., 2000). In this 
pathway, extracellular adenosine levels are elevated by the transport of cAMP to 
the extracellular space where the cAMP is converted to AMP by ecto-
phosphodiesterase (ECTO-PDE) and subsequently to adenosine (ADO) by ecto-
5'-nucleotidase(ECT0-5'-NT) (Fig 23). 





























Fig. 23 A schematic showing the cAMP-adenosine pathway in VSMCs 
Dubey et al., 2000. Hypertension 35:262-6 
 
 
The newly formed adenosine binds the adenosine, subtype 2 receptor, 
(A2) , which has an inhibitory effect on collagen and total protein synthesis. 








mediated through the cAMP-adenosine pathway and not by activation of intracellular 
protein kinase A (PKA) activity. 
The results of these studies, using the phosphodiesterase inhibitor, 
pentoxifylline, showed that by preventing breakdown of cAMP, the cAMP-protein 
kinase A (PKA) pathway may be activated, and this resulted in inhibition of collagen 
synthesis in VSMCs (Chen et al., 1999). Co-incubation of pentoxifylline with H-89, a 
selective inhibitor of PKA, prevented the pentoxifylline induced inhibition of collagen 
synthesis. Since estrogen treatment increases cAMP levels, the role of the cAMP-
PKA pathway in suppressing collagen and total protein synthesis in estrogen- treated 
VSMC tissue culture model was explored. Co-treatment of VSMCs with estrogen 
and Rp-cAMP, a PKA inhibitor, significantly reduced estrogen's ability to inhibit 
collagen and total protein synthesis in VSMCs (Fig.9). These data suggest that in 
our model, estrogen attenuates protein synthesis by activating the cAMP-PKA 
effector pathway. In support of our data, other studies by Walsh et al., (1994), have 
found that PKA can halt translation of proteins by phosphorylating the initiation factor 
elF-2. Possibly, estrogen may impair collagen synthesis by activating a cascade of 
kinases, which are switched on by the PKA pathway. 
To determine if the inhibition of cAMP breakdown to AMP by PDE can 
block the collagen/protein reduction effects of estrogen as suggested by the 
studies of Dubey et al., VSMCs were treated with two different PDE inhibitors. 
Treatment of VSMCs with cilostamide, a phosphodiesterase type Ill inhibitor or 





increased cAMP levels (Fig. 10 and 12) and decreased rates of collagen and 
total protein synthesis (Fig. 11 and 13). Since cilostamide appears to be less 
potent than Ro-20-1724 in elevating cell cAMP levels, it is tempting to speculate 
that inhibition of PDE type IV is more effective than PDE type Ill in elevating 
cAMP levels. Additional dose response studies using both agents would be 
necessary to confirm this.  
Treatment of VSMCs with estrogen and  cilostazol or Ro-20-1724 had an additive 
effect on cAMP levels (Fig. 10 and 12) and on inhibition of collagen and total 
protein synthetic rates ( Fig. 11 and 13). Contrary to the studies by Dubey et al., 
these findings suggest that the breakdown of cAMP to AMP and subsequently to 
adenosine may not be a necessary process for inhibiting protein synthesis in 
VSMCs. The results of our studies using a PKA inhibitor and phosphodiesterase 
inhibitors are consistent with the hypothesis that estrogen- induced changes in 
cAMP activates the cAMP-PKA effector pathway to attenuate protein synthesis 
in VSMCs. 
The phosphodiesterase inhibitor data (cilostamide and  Ro-20-1724) appear 
not to support Dubey's hypothesis that estrogen utilizes the  cAMP- adenosine 
pathway to inhibit collagen synthesis. Instead, our  data  suggest  that estrogen- 
induced cAMP is not required to be converted to adenosine to inhibit collagen 
synthesis. The co-incubation of cilostamide or Ro-20-1724 phosphodiesterase 
inhibitor with estrogen produced an additive effect on cAMP levels and collagen 
inhibition. Furthermore, our beta-adrenergic agonist data bolsters our 
phosphodiesterase inhibitor data because it demonstrates that the beta-adrenergic 






more of its cAMP is exported to the extracellular compartment. 
As shown in figures 11 and 13, the level of protein synthesis inhibition is 
approximately the same in VSMCs treated with cilostamide or Ro-20-1724 even 
though Ro-20-1724 caused a greater increase in cAMP compared to cilostamide 
treated cells. A possible explanation for this observation is that not all the cAMP 
generated by blocking the PDE was available to inhibit protein synthesis. Studies 
have shown that cAMP can be compartmentalized within  the cell and  used for 
activating separate pathways to elicit distinct  biological responses. For example, 
compartmentation studies in the perfused heart have compared effects of forskolin 
and isoproterenol on cAMP accumulation  and cardiac tension. England et al., (1987) 
found that, at approximately equal cardiac tensions, the levels of cAMP elicited by 
isoproterenol were generally smaller than those levels elicited by forskolin. When 
increased concentrations of isoproterenol were used to elevate cAMP to similar 
levels of forskolin treatment, the cardiac tensions were larger with isoproterenol than 
those observed  with  forskolin. England et al. concluded  that only a portion of the 
total cAMP, induced by forskolin, may be responsible for the measured cardiac 
effects and that the remaining cAMP may be collected within intracellular 
compartments involved in different cellular functions. Similar observations were 
made in studies of the relationship of cAMP and the modulation of Ca2 + movement 
through cell membrane calcium channels of isolated canine ventricular myocytes 







Ca2+ correlated best with amount of cAMP in the particulate fraction. As a result, 
treatment of myocytes with isoproterenol resulted in a greater proportion of total 
cAMP in the particulate fraction than with forskolin treatment. Since isoproterenol 
had a greater effect on calcium movement than forskolin, Hohl & Li hypothesized 
that, in myocytes, differences in responses to agents that increased cAMP may be 
explained in part by compartmentalization of cAMP. 
In our experiments, forskolin treatment of VSMCs elevated cAMP levels 
(Fig 14) and suppressed collagen and total protein synthesis (Fig. 15). This 
finding agrees with Dubey et al. (2000) who reported that forskolin treatment has 
an inhibitory effect on collagen synthesis in VSMCs. Our studies showed that co-
incubation of VSMCs with estrogen and forskolin produced an additive effect on 
cAMP production (Fig. 15) and an inhibitory effect on collagen and total protein 
synthesis (Fig. 16). Although the levels of cAMP induced by forskolin (Fig. 15) 
exceeded those induced by estrogen, collagen and total protein inhibition (Fig. 
16) for all these agents was similar (~50% of controls). Based upon the studies 
by England et al., (1987) and Hohl (1991), it can be hypothesized that the bulk 
of the cAMP induced by forskolin may be compartmentalized for alternative 
functions not related to protein synthesis. Studies in human fetal lung fibroblasts 
have shown that treatment of cells with isoproterenol, a beta adrenergic, agonist, 
significantly elevated cAMP content and inhibited collagen synthesis (Baum et 
al., 1981). In our studies, treatment of VSMCs with isoproterenol significantly 




16). As expected, the addition of propranolol, a beta- adrenergic antagonist, to 
isoproterenol treated cells significantly reduced the level of cAMP, which was 
observed in cells treated with isoproterenol alone. Propranolol had no effect on 
estrogen's ability to inhibit cAMP which was not surprising since estrogen has 
been reported to increase cAMP levels by directly stimulating adenylyl cyclase 
activity.(Farhat et al., 1996). 
Surprisingly, isoproterenol had no inhibitory effects on collagen or total 
protein synthetic rates even though isoproterenol treatment  of  VSMCs significantly 
elevated cell cAMP levels (Fig. 16, 17 and 18). Studies by Crystal et  al. (1981) 
reported that a 6- hour incubation of lung fibroblasts with isoproterenol resulted in a 
decrease in collagen synthetic rates. Since our VSMCs were incubated with 
isoproterenol for only 1 hour, a 6-hour incubation study was conducted. As seen in 
figure 19 a 6- hour incubation did not result in any significant alteration in collagen 
or total protein synthetic rates, suggesting that there may be a fundamental 
physiological difference  between  lung  fibroblasts and VSMCs. Treatment of 
VSMCs with isoproterenol and estrogen  had  an additive effect on cAMP levels 
(Fig.16) but had no additive effect on collagen and total protein synthesis (Fig 17 and 
18). The level of inhibition of cellular protein synthesis by this type of combination 
treatment was similar to the  level  of inhibition with estrogen treatment alone (Fig. 
17 and 18). 
VSMCs primarily have beta2 adrenergic receptors that regulate 
vasodilation under normal physiological conditions (Vatner et al., 1986). Since 





adrenergic receptor agonist, was utilized in our studies to further characterize the 
relationship of beta stimulated increases in cAMP and protein synthetic rates. 
Treatment of VSMCs with terbutaline resulted in a significant increase in cAMP 
levels, which was similar to estrogen's effects but was much less than the cAMP 
changes induced by isoproterenol (Fig. 20). As seen with isoproterenol, 
terbutaline also had no effect on protein synthesis in VSMC when administered 
to VSMCs either alone or in combination with estrogen (Fig. 21). 
Numerous studies have shown that activation of the beta-adrenergic 
receptor can mediate transport of cAMP to the extracellular compartment, where 
it can serve an essential cellular function (Rosenberg et al., 1995). For example, 
in cortical cultures, which are co-cultures of neurons and astrocytes, upon 
isoproterenol stimulation of the beta-adrenergic receptor, cAMP is exported out 
from astrocytes to the extracellular compartment where it is hydrolyzed to 
adenosine (Rosenberg et al., 1995). These data suggest that the extracellular 
transport of cAMP is essential in replenishing adenosine levels, which are 
necessary for neuromodulation in the cerebral cortex (Rosenberg et al. 1995). In 
our studies, estrogen and the beta agonists, isoproterenol and terbutaline, had 
induced cAMP, but only estrogen inhibited protein synthesis in VSMCs, 
indicating that estrogen and beta agonist stimulation of cAMP levels result in 
some form of compartmentalization of cAMP within VSMCs. To further examine 
this hypothesis VSMCs were treated with either estrogen or terbutaline, and the 
distribution patterns of cAMP  were measured. In VSMCs, treated with 




extracellular and 10% intracellular, while in VSMCs, treated with estrogen, the 
cAMP distribution pattern was 70% extracellular and 30% intracellular. The 
distribution of cAMP following estrogen treatment was similar to the distribution 
of cAMP seen in untreated VSMCs. (Fig. 22). These data suggest that the 
transport of cAMP to the extracellular compartment following treatment with a 
beta agonist may explain why beta -adrenergic stimulation of cAMP in VSMCs 
does not result in inhibition of protein synthesis in VSMCs. (Fig.22). Since beta-
adrenergic stimulation results in increased levels of cAMP in the extracellular 
compartment, it further questions the significance of the adenosine pathway as 
described by Dubey et al. (2000) in regulating protein synthesis in VSMCs. 
Conclusion 
 
The hypothesis, which was investigated in this study, was that  agents which 
elevate cAMP in VSMC when used in combination  with estrogen will have an 
additive effect in inhibiting collagen synthesis in VSMC. Our studies  found that 
phosphodiesterase Ill inhibitor, cilostamide, phosphodiesterase IV inhibitor, Ro-24-
1724. and forskolin in combination with estrogen had additive effects on estrogen 
induced cAMP levels and on estrogen reduced collagen synthetic rates, while beta-
adrenergic agonists, isoproterenol or terbutaline, when used in combination with 
estrogen were able to elicit an additive effect on cAMP levels but had no effect on 
collagen synthetic rates.  Furthermore,  our studies show that once the beta- 
adrenergic receptor stimulation induces cAMP, it is actively transported to the 
extracellular milieu. These data suggest  that the loss of most cAMP due to its 






beta- adrenergic receptor stimulation is unable to inhibit collagen synthesis in 
VSMCs. 
Our study has shown that estrogen and other camp elevating agents, such 
as cilostamide, Ro-20-1724, and forskolin, have an inhibitory effect on collagen 
synthesis  in VSMCs.   It  is well established  that during the later stages  of  lesion 
development  reducing  collagen  content  in lesions  may  weaken  lesions and 
 
cause them to rupture. The clinical significance of the data is that estrogen 
replacement therapy and medications which elevate cAMP may reduce collagen 
levels in lesions, causing them to eventually rupture. Furthermore, our data also 
suggest that the combination of these agents, which have an additive effect on 
estrogen, may have a negative effect on the stability of existing atherosclerotic 
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